

February 05, 2026

Evonik sets new dividend policy, meets guidance for 2025

- **Annual shareholder distribution to become dynamic**
- **Guidance for 2025 met: adjusted EBITDA €1.874 billion**
- **Outlook for 2026: adjusted EBITDA between €1.7 and €2.0 billion**

Essen, Germany. At today's meeting, the Executive Board discussed Evonik's dividend policy based on the preliminary results for 2025 and the outlook for 2026. As reported in an ad hoc announcement earlier today, Evonik targets an annual shareholder distribution of between 40 and 60 percent of adjusted net income starting with the 2026 financial year. The measure is introduced to increase financial flexibility. For the fiscal year 2025, the company plans to distribute €1.00 per share as a transition to the future dividend policy. This corresponds to a current dividend yield of about 7 percent. Previously, the annual dividend amounted to €1.17 per share.

"We need a good balance between appropriate shareholder profit sharing and the ability to invest in the best future projects at the proper time and decrease leverage further," says Christian Kullmann, Chairman of the Executive Board. "Our new dividend policy improves that balance."

Evonik has met its earnings guidance for 2025. According to preliminary, unaudited results, adjusted EBITDA amounted to €1.874 billion, in line with the guidance of around €1.9 billion.

At €14.1 billion, sales in 2025 were about 7 percent below the previous year. The cash conversion rate of 37 percent reached the upper end of the target range of 30 to 40 percent, based on a strong free cash flow of €695 million.

"The high level of cash generation is remarkable and sets Evonik apart," says Claus Rettig, who is temporarily handling operations at the finance department. "We are

comfortably covering the planned shareholder distribution and are in an excellent competitive position."

The Chief Financial Officer position, which became vacant in September, is to be filled by the 2026 Annual General Meeting. Evonik reported net income of €265 million for 2025 (2024: €222 million).

In 2025, the efficiency program Evonik Tailor Made helped to reduce hierarchies and accelerate decision-making. In the current year, it will further contribute to planned cost reductions, partly by eliminating as many as 2,000 jobs. SYNEQT, the operating company for the German chemical parks in Marl and Wesseling, became an independent entity at the beginning of the year.

The economic environment remains challenging in 2026. Therefore, Evonik expects an adjusted EBITDA of between €1.7 and €2.0 billion for the current fiscal year. In the medium term, Evonik is fully focused on its goal of earning a return on capital employed (ROCE) of 11 percent.

Evonik will publish 2025 full-year results on March 4, 2026, as previously scheduled.

Contacts

Jörg Wagner

Head of External Communications

Tel +49 201 177-3408

joerg2.wagner@evonik.com

Richard Weiss

External Communications: Finance, Region Americas

Tel +49 201 177-2532

Mobile +49 174 233 8658

richard.weiss@evonik.com

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany

Phone +49 201 177-01
www.evonik.com

Supervisory Board Bernd Tönjes,
Chairman Executive Board Christian
Kullmann, Lauren Kjeldsen, Dr.
Claudine Mollenkopf, Thomas Wessel

Registered Office is Essen Register
Court Essen Local Court Commercial
Registry B 19474

[Online version press release](#)